Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 17

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Chronic lymphocytic leukaemia+3

Recruiting

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Diffuse large B-cell lymphoma refractory

Recruiting

Study to Optimize Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Stichting Radboud University Medical Center

Diffuse large B-cell lymphoma

Recruiting

Study of Rituximab and Golcadomide for Older Frail Patients with Diffuse Large B-cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Golcadomide
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute myeloid leukaemia refractory+1

Recruiting

Study on the Safety and Effectiveness of Eltanexor for Patients with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ELTANEXOR
  • Sponsor:Azienda Ospedaliero Universitaria Delle Marche

Acute lymphocytic leukaemia

Recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Cardiff University

Systemic mastocytosis

Recruiting

Study on Dupilumab and Fexofenadine for Treating Indolent Systemic Mastocytosis with Skin Involvement in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Gdansk

Diffuse large B-cell lymphoma refractory+2

Recruiting

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Chronic lymphocytic leukaemia+2

Recruiting

Study of IDP-121 for Patients with Relapsed or Refractory Multiple Myeloma, B-cell Lymphoma, or Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IDP-121
  • Sponsor:Idp Discovery Pharma S.L.

Plasma cell leukaemia

Recruiting

Study on the Effectiveness and Safety of Bortezomib and Daratumumab for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Hellenic Society Of Hematology

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.